This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Mark Alden Hermsmeier: Innovator in Chemokine Receptor Modulation
Introduction
Mark Alden Hermsmeier is a notable inventor based in Somerville, NJ (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate chemokine receptor activity. His work is essential in understanding and potentially treating various diseases.
Latest Patents
Hermsmeier holds a patent for "Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity." This patent represents a crucial advancement in the search for new therapeutic agents that can influence immune responses.
Career Highlights
Hermsmeier is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role involves research and development, focusing on innovative solutions to complex health challenges.
Collaborations
Throughout his career, Hermsmeier has collaborated with esteemed colleagues, including David Brent Rawlins and John Wityak. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Mark Alden Hermsmeier's contributions to the field of chemokine receptor modulation highlight his innovative spirit and dedication to advancing medical science. His work continues to inspire future research and development in pharmacology.